INMD241220C20000
- 0.03
- 0.000.00%
InMode Newsroom
Barclays Maintains InMode(INMD.US) With Buy Rating, Cuts Target Price to $26
Needham Remains a Hold on InMode (INMD)
BTIG Maintains InMode(INMD.US) With Buy Rating, Maintains Target Price $25
Analysts Offer Insights on Healthcare Companies: InMode (INMD) and Sana Biotechnology (SANA)
InMode Lowers 2024 Revenue Guidance; Sets 2025 Revenue Outlook; Shares Slump Pre-Bell
InMode Cuts FY24 Revenue Outlook From $410M - $420M To $394M - $394.5M, Est $411.188M
InMode Expects Q4 Revenue Of $97.0M-$97.5M (Est $114.22M); Preliminary Results Reflect Stronger-than-Expected Headwinds In Aesthetics Industry
InMode to Report Fourth Quarter & Full Year 2024 Financial Results and Hold Conference Call on February 6, 2025, Expects Q4 Revenue Between $97.0M-$97.5M
Is InMode Ltd.'s (NASDAQ:INMD) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Is There An Opportunity With InMode Ltd.'s (NASDAQ:INMD) 49% Undervaluation?
Why Is InMode Ltd. (INMD) Among the Best Cosmetic Surgery and Aesthetics Stocks to Invest In Now?
The Returns On Capital At InMode (NASDAQ:INMD) Don't Inspire Confidence
InMode's (NASDAQ:INMD) Earnings Have Declined Over Three Years, Contributing to Shareholders 77% Loss
InMode (NASDAQ:INMD) Might Be Having Difficulty Using Its Capital Effectively
InMode to Present at Upcoming Investor Conferences
We Think You Can Look Beyond InMode's (NASDAQ:INMD) Lackluster Earnings
UBS Adjusts Price Target on InMode to $19 From $17, Maintains Neutral Rating
InMode Analyst Ratings
Needham Maintains InMode(INMD.US) With Hold Rating
Hartwater Aesthetics CEO to Deliver Keynote Address at Upcoming Industry Conference